Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background Direct acting anti-HCV drugs have demonstrated a high cure rate and favorable tolerability. The development of shorter courses of therapy may improve affordability and adherence. Sofosbuvir and ledipasvir together with ribavirin have yielded high efficacy when administered for 8, but not for 6 weeks. We hypothesized that addition of a third potent directly acting antiviral to sofosbuvir and ledipasvir would allow for shortened durations of therapy. Methods In this single center, open-label cohort, phase 2 atrial, sixty HCV GT-1 treatment naïve patients were sequentially enrolled onto three arms and treated with 12 weeks of sofosbuvir and ledipasvir (an NS5B nucleotide polymerase inhibitor and an NS5A inhibitor, respectively) (n=20); or 6 weeks with sofosbuvir, ledipasvir, and GS-9669 (a non-nucleoside NS5B inhibitor) (n=20) or 6 weeks with sofosbuvir, ledipasvir and GS-9451 (an NS3/4A protease inhibitor) (n=20). Patients and investigators were unmasked to treatment assignment. The primary efficacy analysis was SVR12 (HCV RNA less than the level of quantitation 12 weeks after treatment completion). Findings All subjects treated with sofosbuvir and ledipasvir for 12 weeks achieved SVR12 (95%CI: 83–100%). Nineteen of 20 patients (95% CI: 75–100%) treated with sofosbuvir, ledipasvir and GS-9669 achieved SVR12, with 1 patient relapsing 2 weeks after completion of therapy. Nineteen of 20 patients (95% CI: 75–100%) treated with sofosbuvir, ledipasvir, and GS-9451 for 6 weeks achieved SVR12, one patient was lost to follow up after achieving SVR4. There were no discontinuations of treatment due to adverse events. Interpretation In this small proof of concept study, two different three drug regimens administered for 6 weeks resulted in high cure rates for HCV infection with excellent tolerability. Funding NIAID, National Cancer Institute and Clinical Center Intramural Program. Clinical Trials.gov number NCT01805882. The study was also supported in part by the German Research Foundation (DFG) by the clinical research unit KFO 129 and a Collaborative Research and Development Agreement between NIH and Gilead Sciences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu012 · Cited by 216
Cited by
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 607
van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271
Hepatitis C virus NS3/4a protease inhibitors
McCauley, J. A., & Rudd, M. T. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.015 · Cited by 120
Advances in hepatitis C therapy: what is the current state - what come's next?
Zopf, S. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i3.139 · Cited by 91
Weber, E. W., Lynn, R. C., Parker, K. R., Anbunathan, H., Lattin, J., Sotillo, E., Good, Z., Malipatlolla, M., Xu, P., Vandris, P., et al. (2020) · doi:10.1101/2020.01.26.920496 · Cited by 18
“Indeed, improved antigen-specific T cell function has been associated with antigen clearance in humans with hepatitis C infection treated with direct acting anti-viral therapies (Burchill et al., 2015; Kohli et al., 2015; Martin et al., 2014; Shrivastava et al., 2017; Wieland et al., 2017).”
Background
Metadata
- Authors
- Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E. G., Barrett, L. L., Bon, D., Marti, M. M., Silk, R., Kotb, C., Gross, C., Jolley, T. A., Sidharthan, S., Petersen, T., Townsend, K., Egerson, D., Kapoor, R., Spurlin, E., Sneller, M., Proschan, M., Herrmann, E., Kwan, R., Teferi, G., Talwani, R., Diaz, G., Kleiner, D. E., Wood, B. J., Chavez, J., Abbott, S., Symonds, W. T., Subramanian, G. M., Pang, P. S., McHutchison, J., Polis, M. A., Fauci, A. S., Masur, H., & Kottilil, S.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 385
- Issue
- 9973
- Pages
- 1107-1113
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2151063300
- Cited by
- 150
- References
- 1
- FWCI
- 17.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. https://app.cochat.ai/papers/10.1016/s0140-6736(14)61228-9
- The paper
- Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E. G., Barrett, L. L., Bon, D., Marti, M. M., Silk, R., Kotb, C., Gross, C., Jolley, T. A., Sidharthan, S., Petersen, T., Townsend, K., Egerson, D., Kapoor, R., Spurlin, E., Sneller, M., . . . Kottilil, S. (2015). Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. The Lancet. https://doi.org/10.1016/s0140-6736(14)61228-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.